Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression

American Journal of Pathology

Volumn 162, Issue 3, 2003, Pages 849-860

  Sgambato, Alessandro ^a   Migaldi, Mario ^b   Montanari, Micaela ^a   Camerini, Andrea ^a   Brancaccio, Andrea ^a   Rossi, Giulio ^b   Cangiano, Rodolfo ^a   Losasso, Carmen ^a   Capelli, Giovanni ^a   Trentini, Gian Paolo ^b   Cittadini, Achille ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROGLYCAN; MESSENGER RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL LINE; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN MCF 7; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

EID: 0345505670     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63881-3     Document Type: Article

References (38)

1. Durbeej M, Henry MD, Ferletta M, Campbell KP, Ekblom P: Distribution of dystroglycan in normal adult mouse tissues. J Histochem Cytochem 1998, 46:449-457
2. Winder SJ: The complexities of dystroglycan. Trends Biochem Sci 2001, 26:118-124
3. Holt KH, Crosbie RH, Venzke DP, Campbell KP: Biosynthesis of dystroglycan: processing of a precursor peptide. FEBS Lett 2000, 468:79-83
4. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP: Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992, 355:696-702
5. Ibraghimov-Beskrovnaya O, Mialtovich A, Ozcelik T, Yang B, Koepnick K, Francke U, Campbell KP: Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization. Hum Mol Genet 1993, 2:1651-1657
6. Ervasti JM, Campbell KP: Dystroglycan: an extracellular matrix receptor linked to the cytoskeleton. Curr Opin Cell Biol 1996, 8:625-631
7. Russo K, Di Stasio E, Macchia G, Rosa G, Brancaccio A, Petrucci TC: Characterization of the beta-dystroglycan-growth factor receptor 2 (Grb2) interaction. Biochem Biophys Res Commun 2000, 274:93-98
8. Williamson RA, Henry MD, Daniels KJ, Hrstka RF, Lee JC, Sunada Y, Ibraghimov-Beskrovnaya O, Campbell KP: Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet 1997, 6:831-841
9. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP: Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990, 345:315-319
10. Ohlendieck K, Matsumura K, Ionasescu VV, Towbin JA, Bosch EP, Weinstein SL, Sernett SW, Campbell KP: Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology 1993, 43:795-800
11. Losasso C, Di Tommaso F, Sgambato A, Ardito R, Cittadini A, Giardina B, Petrucci TC, Brancaccio A: Anomalous dystroglycan in carcinoma cell lines. FEBS Lett 2000, 484:194-198
12. Yamada H, Salto F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, Okuyama A, Maekawa R, Shimizu T, Matsumura K: Processing of β-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genetics 2001, 10:1563-1569
13. Sciandra F, Schneider M, Giardina B, Baumgartner S, Petrucci TC, Brancaccio A: Identification of the β-dystroglycan binding epitope within the C-terminal region of α-dystroglycan. Eur J Biochem 2001, 268:4590-4597
14. Henry MD, Cohen MB, Campbell KP: Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol 2001, 32:791-795
15. Kip1 expression. Cell Growth Differ 1997, 8:393-405
16. Bearhs OH, Henson DE, Hutter RVP, Kennedy BJ: Manual for Staging of Cancer. Philadelphia, J. B. Lippincott, 1992
17. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410
18. Kip1 in human colon cancer. Mol Carcinog 1999, 26:172-179
19. Kip1 in human breast cancers. Clin Cancer Res 1997, 3:1879-1887
20. Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999, 13:3245-3250
21. Zunarelli E, Nicoll JA, Migaldi M, Trentini GP: Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome. Breast Cancer Res Treat 2000, 63:193-198
22. Rallo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K, Nordling S: Ki67, p53, ER receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 1997, 36:369-374
23. Mirza AN, Mirza NQ, Vlastos G, Singletary SE: Prognostic factors in node-negative breast cancer. Ann Surg 2002, 235:10-26
24. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983, 31:1933-1935
25. Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, De Gaetani C, Capelli G, Cittadini A, Trentini GP: Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002, 97:671-678
26. Hiddemann W, Schumann J, Andreeff M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF, Sandberg AA: Convention on nomenclature for DNA cytometry. Cytometry 1984, 5:445-446
27. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526
28. Clark GM: Interpreting and integrating risk factors for patients with primary breast cancer. J Natl Cancer Inst Monogr 2001, 30:17-21
29. Costa SD, Lange S, Klinga K, Merkle E, Kaufmann M: Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer - results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer 2002, 38:1329-1334
30. Schnitt SJ: Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 2001, 30:22-26
31. Hanahan D, Weinberg RA: The hallmark of cancer. Cell 2000, 100:57-70
32. Maekawa R, Maki H, Yoshida H, Hojo K, Tanaka H, Wada T, Uchida N, Takeda Y, Kasai H, Okamoto H, Tsuzuki H, Kambayashi Y, Watanabe F, Kawada K, Toda K, Ohtani M, Sugita K, Yoshioka T: Correlation of antiangiogenic and antitumor efficacy of N-biphenylo sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res 1999, 59:1231-1235
33. Bonkhoff H, Wernert M, Dhom G, Remberger K: Distribution of basement membranes in primary and metastatic carcinomas of the prostate. Hum Pathol 1992, 23:408-421
34. Ozzello L: The behavior of basement membranes in intraductal carcinoma of the breast. Am J Pathol 1959, 35:887-900
35. Hayman EG, Engvall E, Ruoslahti E: Concomitant loss of cell surface fibronectin and laminin from transformed rat kidney cells. J Cell Biol 1981, 88:352-357
36. Hynes RO, Wyke JA: Alterations in surface proteins in chicken cells transformed by temperature-sensitive mutants of Rous sarcoma virus. Virology 1975, 64:492-504
37. Yang B, Jung D, Motto D, Meyeer J, Koretzky G, Campbell KP: SH3 domain mediated interaction of dystroglycan and Grb2. J Biol Chem 1995, 270:11711-11714
38. Chardin P, Cussac D, Maignan S, Ducruix A: The Grb2 adaptor. FEBS Lett 1995, 369:47-51